Evidence Regarding Pharmacogenetics in Pain Management and Cancer

D. Max Smith*, William D. Figg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Patients experience interindividual variation in response to analgesics, which may be partially explained by genetics.This commentary discusses a recently published trial on COMT genotype and opioid dose requirements and describes the potential role for COMT and other genes (eg, CYP2D6) on opioid therapy and the current evidence for germline pharmacogenetics and resources for opioid pharmacogenetics.

Original languageEnglish
Pages (from-to)189-192
Number of pages4
JournalOncologist
Volume28
Issue number3
DOIs
StatePublished - Mar 2023
Externally publishedYes

Keywords

  • cancer pain
  • opioids
  • pain
  • pharmacogenetics
  • pharmacogenomics

Fingerprint

Dive into the research topics of 'Evidence Regarding Pharmacogenetics in Pain Management and Cancer'. Together they form a unique fingerprint.

Cite this